Objective We examined the effects of tumor necrosis factor-a (TNF-a) on expression and release of interleukin-6 (IL-6) by human urothelial cells (HUCs) and investigated whether the effects of TNF-a are mediated by mitogenactivated protein kinase (MAPK) pathways. Materials and methods HUCs were treated with TNF-a at 1-10 ng/ml for 2-24 h. Expression of IL-6 and TNF-a receptor 1 (TNFR1) mRNAs were examined by real-time PCR. The release of IL-6 into culture medium was determined by ELISA. The presence of TNFR1 protein and TNF-a-induced activation of MAPK pathways was examined by immunoblotting analysis. The effects of selective blockers of MAPK pathways on TNF-a-induced IL-6 expression and release were determined. Results TNF-a increased IL-6 mRNA expression and stimulated release of IL-6 in a concentration-and timedependent manner. The effects of TNF-a were mediated by TNFR1. TNF-a induced phosphorylation of ERK1/2 and JNK, and TNF-a-induced IL-6 expression and release were inhibited by selective ERK1/2 and JNK blockers. Conclusions These results demonstrate that TNF-a increases expression and release of IL-6 by HUCs and that the effects of TNF-a are mediated by TNFR1. Also, the ERK1/2 and JNK pathways are involved in TNF-a-induced expression and release of IL-6 in HUCs and may represent therapeutic targets in inflammatory urinary tract diseases.
Introduction
Tumor necrosis factor-a (TNF-a) is a pro-inflammatory cytokine that is primarily produced by activated macrophages, T lymphocytes, and mast cells [1, 2] . TNF-a is the most rapidly produced pro-inflammatory cytokine during activation of innate host defenses [3] , and epithelial and endothelial cells are primary targets of TNF-a [4] . TNF-a exerts multiple effects on targeted cells, including stimulating production and release of inflammatory cytokines by these cells [5] . To date, two subtypes of TNF-a receptors, 1 and 2, have been identified, and most effects of TNF-a appear to be mediated by the TNF-a receptor 1 (TNFR1) [1, 2, 6] . Binding of TNF-a to TNFR1 triggers a series of intracellular events, including activation of mitogen-activated protein kinase (MAPK) pathways [7] .
Interleukin-6 (IL-6) is a multifunctional cytokine involved in innate host defense and inflammatory responses, and IL-6 production is increased during various inflammatory conditions [8] . IL-6 cannot be detected in urine from healthy persons, but urine IL-6 concentrations are increased in children and adults with urinary tract infection [9] . IL-6 is also significantly increased in urine from patients with inflammatory bladder diseases [10] , suggesting that IL-6 may participate in pathology underlying inflammatory urinary tract diseases [10] .
Besides acting as a barrier separating the environment and submucosal tissues, urothelial cells play an important role in regulating urinary tract functions by producing and releasing a number of signaling molecules including cytokines [18, 19] . In the present study, we examined the effects of TNF-a on expression and release of IL-6 from cultured human urothelial cells (HUCs) and investigated whether the effects of TNF-a are mediated by MAPK pathways.
Materials and methods

Culture of HUCs
HUCs were derived from segments of ureter obtained from a healthy donor as a byproduct of kidney transplant surgery in the absence of cancer, active infection, or other bladder disorders, and immortalized by human papillomavirus E6 as described previously [11, 12] . The use of HUCs was reviewed and approved by University of WisconsinMadison Health Sciences Institutional Review Board. Cells were cultured in Ham's F12 medium (Invitrogen, Carlsbad, CA, USA), supplemented with 0.1 lg/ml hydrocortisone, 5 lg/ml transferin, 10 lg/ml insulin, 0.1 mM nonessential amino acid, 27 mg/ml dextrose, 2.0 mM L-glutamine, 100 l/ml penicillin, 100 lg/ml streptomycin, and 2% fetal bovine serum [12] .
Measurement of IL-6 by ELISA HUCs were seeded in 12-well plates (*50,000 cells/well), 2 ml medium per well. Cells were allowed to grow to 70-80% confluence and treated with test drugs for various times, and control cells were treated with vehicles used to prepare drugs. Conditioned medium was then collected, and IL-6 was measured using paired IL-6 antibodies from R&D Systems (Human IL-6 DuoSet; Minneapolis, MN, USA) following the manufacturer's instructions. Samples were diluted 1:1 in sample buffer and run in duplicate.
Immunoblotting
Cells were grown in 25 cm 2 flasks (*200,000 cells/flask). Cell lysates were prepared using a commercial mammalian cell extraction reagent (Pierce, Rockford, IL, USA) with a protease inhibitor cocktail (Roche Diagnostics, Indianapolis, IN, USA) added immediately prior to protein isolation. Cell lysates were collected by centrifuging at 10,000g for 30 min at 4°C. Protein content was determined by the Bradford assay (Pierce). 20 lg of protein sample per lane was loaded and resolved on 10% SDS gel by electrophoresis and transferred to nitrocellulose membranes. Membranes were blocked in 10% fat-free dry milk in TBST (20 mM Tris-HCl, 137 mM NaCl, 0.05% Tween-20; pH 7.5) for 1 h and incubated with primary antibody overnight at 4°C. Membranes were then washed free of primary antibody and incubated at room temperature for 1 h with secondary antibody conjugated with horseradish peroxidase. Signals were revealed with ECL detection reagent (Pierce). Membranes were stripped and re-blotted with a-tubulin antibody as a loading control.
Real-time reverse transcription-PCR analysis
HUCs were seeded in 6-well plates (*100,000 cells/well). Total RNA was isolated using RNeasy Ò Mini Kits (Qiagen, Valencia, CA, USA) and treated with DNAse I (Invitrogen) to remove genomic DNA. First-strand cDNA was generated using a cDNA synthesis kit (Invitrogen) according to the manufacturer's instructions. Primers were designed using Primer Express Ò software (Applied Biosystems, Foster City, CA, USA) from gene sequences obtained through GenBank. PCR was performed using an ABI 7300 instrument (Applied Biosystems), and SYBR Green was used to reveal real-time PCR product accumulation. Samples were amplified in duplicate using the following thermal cycling conditions: 94°C for 10 min, followed by 40 cycles of amplification at 94°C for 30 s and then 60°C for 1 min to allow for denaturing and annealing-extension, and expression level of IL-6 was normalized to expression of human S26, a constitutively expressed ribosomal protein in the same sample. Primer sequences used were: IL-6 (forward: 
Reagents
Polyclonal rabbit anti-TNFR1 (1:1,000), monoclonal antia-tubulin (1:10,000), monoclonal anti-JNK-2 (1:500) antibodies, and secondary goat anti-rabbit IgG and goat anti-mouse IgG (both conjugated to horseradish peroxidase and used at 1:20,000 dilution) were obtained from Santa Cruz (Santa Cruz, CA, USA). Polyclonal rabbit anti-phospho-ERK1/2 (1:1,000), phospho-p38 (1:1,000), pan-ERK1/ 2 (1:1,000), and p38 (1:1,000) antibodies were obtained from Cell Signaling (Danvers, MA, USA). Polyclonal rabbit anti-phospho-JNK2 (1:3,000) antibody was from Promega (Madison, WI, USA). U0125, U0126, and SP600125 (dissolved with DMSO at 10 mM as the stock solution and diluted in PBS to desired concentration) were obtained from EMD Chemicals (Gibbstown, NJ, USA). SB202474 DiHCl and SB203580 HCl (EMD Chemicals) were dissolved in PBS. U0126 is a selective ERK1/2 inhibitor, and U0125 is structurally similar to U0126 and is used as the inactive control congener of U0126. SB203580 HCl is a selective p38 kinase inhibitor, and SB202474 DiHCl is an inactive control congener. SP600125 is a selective JNK kinase inhibitor, but no inactive control congener is available [13] . Recombinant human TNF-a, goat polyclonal TNFR1 agonistic antibody, and monoclonal TNFR1 neutralizing antibody were from R&D Systems, and these antibodies selectively recognize different epitopes of TNFR1. TNFR1 antibodies that activate TNFR1 exert an agonistic effect [15] , and those that prevent binding of TNF-a to TNFR1 neutralize the effects of TNF-a [16, 17] .
Statistical analysis
Data are presented as arithmetic means ± SEM. Data were analyzed using one-way ANOVA followed by Tukey's post hoc multiple comparison test (GraphPad Prism, San Diego, CA, USA). A p value \0.05 was considered indicative of significant differences.
Results
TNF-a increased IL-6 expression and release by HUCs
HUCs were treated with TNF-a at various concentrations (1-10 ng/ml) for 6 h. TNF-a stimulated IL-6 release in a concentration-dependent manner, and the effect of TNF-a appeared to reach a maximum at 10 ng/ml (Fig. 1a) . HUCs were therefore treated with TNF-a at a submaximal concentration of 3 ng/ml for various periods of time, and medium was collected to measure IL-6 release. TNF-a (3 ng/ml) increased IL-6 release in a time-dependent manner (Fig. 1b) . TNF-a (3 ng/ml) also enhanced IL-6 mRNA expression, and the effect of TNF-a on IL-6 mRNA expression peaked 1 h after exposure to TNF-a. IL-6 mRNA content remained increased 4, 8, and 12 h after treatment with TNF-a compared to controls at each time point (Fig. 1c) .
Effects of TNF-a were mediated by TNFR1 TNFR1 protein (Fig. 2a) and mRNA ( Fig. 2b) were present in HUCs, and treatment with TNF-a (3 ng/ml) did not alter expression of TNFR1 (Fig. 2a, b) . Treatment of HUCs with a selective TNFR1 agonistic antibody (5 lg/ml) [15] stimulated IL-6 release by about 5-fold compared to concentrations of IL-6 in control samples treated with the same amount of normal goat IgG ( Fig. 2c ; n = 6, p \ 0.01 vs. control). IL-6 release induced by TNF-a (3 ng/ml, for 6 h) was prevented by a selective TNFR1 neutralizing antibody Fig. 2d ; n = 6, p \ 0.01 vs. control), and control samples were treated with the same amount of normal mouse IgG.
Effects of TNF-a were mediated by ERK1/2 and JNK MAPK pathways TNF-a (3 lg/ml) induced phosphorylation of ERK1/2 15 min after application of TNF-a ( Fig. 3a; n = 4) . Incubation of TNF-a (3 lg/ml) for 1 h increased expression of IL-6 mRNA (Fig. 3b) , and IL-6 release (Fig. 3c) was enhanced by TNF-a (3 lg/ml) for 6 h. These effects of TNF-a were inhibited (p \ 0.01 vs. TNF-a-treated group, n = 6) by pretreatment with U0126 (10 lM), an inhibitor of ERK1/2 phosphorylation, but not by its inactive congener U0125 (p [ 0.05 vs. TNF-a-treated group, n = 6), applied 15 min before TNF-a ( Fig. 3d and e) . TNF-a (3 lg/ml) also induced phosphorylation of JNK-2 15 min after application of TNF-a ( Fig. 4a ; n = 4). Incubation of TNF-a (3 lg/ml) for 1 h increased expression of IL-6 mRNA (Fig. 4b) , and IL-6 release (Fig. 4c) was enhanced by TNF-a (3 lg/ml) for 6 h. These effects of TNF-a were inhibited (p \ 0.01 vs. TNF-a-treated group, n = 6) by pretreatment with SP600125 (10 lM), an inhibitor of JNK, applied 15 min before TNF-a (Fig. 4b) .
Treatment of HUC with TNF-a (3 lg/ml) failed to induce phosphorylation of p38 ( Fig. 5a ; n = 4). Lysates of PC12 cells treated with nerve growth factor (provided by Cell Signaling) as a positive control were subjected to electrophoresis on the same gel as lysates of HUCs, demonstrating that the antibody was able to detect p38 MAPK phosphorylation in PC12 cells using this immunoblotting protocol (data not shown), and the absence of a specific signal in urothelial cells (Fig. 5a ) indicated that TNF-a indeed did not induce p38 MAPK phosphorylation in urothelial cells. Although TNF-a (3 lg/ml, for 1 h)-induced expression of IL-6 mRNA (Fig. 5b ) and IL-6 release (TNF-a, 3 lg/ml, for 6 h, Fig. 5c ) were inhibited (p \ 0.01 vs. TNF-a-treated group, n = 6) by pretreatment with SB 203580 (10 lM; an inhibitor of p38 applied 15 min before TNF-a), SB202474 (the inactive congener of SB203580) also induced a similar inhibition on the expression of IL-6 mRNA and IL-6 release (p \ 0.01 vs. TNF-a-treated group, n = 6) (Fig. 5b) . These results indicate that inhibition of IL-6 expression and release by SB203580 is not specific to the p38 pathway.
Discussion
In the present study, we found that: (1) treatment with TNF-a increased expression and release of IL-6 by HUCs; were present in the HUCs, and treatment with TNF-a (3 ng/ml) did not alter expression of TNFR1. The relative TNFR1 mRNA expression level was normalized to expression of human S26 mRNA, a constitutively expressed ribosomal protein in the same sample. Data are presented as mean ± SEM of 6 replicates. c Treatment of HUCs with a selective TNFR1 agonistic antibody (5 lg/ml) stimulated IL-6 release. Data are presented as mean ± SEM of 6 replicates. d IL-6 release induced by TNF-a (3 ng/ml, for 6 h) was prevented by a selective TNFR1 neutralizing antibody (2.5 lg/ml) applied 15 min before TNF-a. Data are presented as mean ± SEM of 6 replicates. **p \ 0.01 versus control group. (2) the effects of TNF-a were mediated by TNFR1; and (3) TNF-a-induced IL-6 expression and release were at least partly mediated by the MAPKs ERK1/2 and JNK pathways. Previous studies have shown an increase in mast cell numbers and activation in inflammatory diseases of the urinary tract [14] . TNF-a is a major cytokine secreted by activated mast cells. Mast cell-derived TNF-a has been shown to induce IL-8 release from urothelial cells, and the effects of TNF-a on urothelial cells are mediated by TNFR1 [5] . The present study demonstrates that TNF-a stimulates expression and release of IL-6 by urothelial cells, and the effect of TNF-a on IL-6 release was concentration-and time-dependent. IL-6 was significantly increased in urine from patients with inflammatory bladder diseases [10] . Our data suggest that urothelial cells respond to inflammatory stimuli by synthesizing and releasing IL-6 and may participate in pathology of inflammatory urinary tract diseases.
TNFR1 is a 55-kD protein expressed in various cell types [12] and primarily mediates effects of TNF-a [1, 2, 6] . Our data demonstrate that TNFR1 is present in urothelial cells and that expression of TNFR1 was not affected by treatment with TNF-a. Recently, selective antibodies against different epitopes of TNFR1 have been developed. Some of the antibodies bind to TNFR1 and induce activation of TNFR1, exerting an agonistic effect [15] , and others prevent binding of TNF-a to TNFR1, neutralizing the effects of TNF-a [16, 17] . In the present study, the selective TNFR1 agonistic antibody induced IL-6 release, and the selective TNFR1 neutralizing antibody abolished TNF-a-induced IL-6 release from HUCs. Therefore, our data suggest that the effects of TNF-a on IL-6 release by HUCs are mediated by TNFR1.
As an inflammatory mediator, IL-6 has been shown to increase sensitivity of afferent nerve fibers during inflammation [18] . IL-6 receptors are expressed in afferent neurons and their nerve fibers, suggesting that IL-6 may directly affect afferent function, and administration of IL-6 into rat paws induced hyperalgesia in a dose-dependent manner [20] . In combination with its soluble receptors, IL-6 sensitized skin afferent nociceptors and increased release of calcitonin-gene-related peptide [21] . Pretreatment with IL-6 neutralizing antiserum inhibited carrageenin-induced hyperalgesia in rats [20] . Afferent nerve fibers in the urinary tract are located in close proximity to urothelial cells, suggesting that chemical mediators derived from urothelial cells can significantly influence function of afferent nerve fibers [18] . Interestingly, IL-6 concentrations in urine correlated positively with pain scores in patients with inflammatory bladder diseases [10] . Increased expression and release of IL-6 during inflammation may therefore contribute to increased afferent functions in patients with inflammatory urinary tract disorders.
The MAPKs are a group of protein serine/threonine kinases that mediate signal transduction from the cell surface to the nucleus in response to a variety of extracellular stimuli [22, 23] . The MAPKs consist of three major families of protein kinases, including p38, ERK, and JNK [22, 23] , and activity of MAPKs depends on their phosphorylation status [22, 23] . In human neutrophils, TNF-a suppresses apoptosis through activation of both ERK1/2 and p38 pathways [17] . TNF-a-induced IL-6 release was mediated by p38 pathways in rheumatoid synovial fibroblasts and airway smooth muscle cells [15] . In human pulmonary microvascular endothelial cells [24] and murine embryo fibroblasts [25] , TNF-a induced activation of JNK pathways. Thus, TNF-a is capable of activating all three major MAPK pathways, although activation of ERK1/2, p38, or JNK by TNF-a may vary among cell types. We found that TNF-a induced phosphorylation of ERK1/2 and JNK in HUCs. Moreover, IL-6 mRNA expression and release induced by TNF-a were inhibited by selective antagonists of ERK1/2 and JNK. These results suggest that both ERK1/2 and JNK pathways mediate TNF-a-induced expression and release of IL-6 in HUCs. TNF-a did not induce phosphorylation of p38 in HUCs. Although TNF-ainduced IL-6 mRNA expression and release were moderately inhibited by a selective p38 blocker (SB 203580), the effects of TNF-a were also reduced by the inactive p38 blocker congener (SB 202474), suggesting that inhibition of the effects of TNF-a by these chemicals may not be related to specifically blocking the p38 pathway. Similarly, Bellei et al. [26] reported that SB203580 and SB202474 inhibited melanin synthesis in B16 melanoma cells and the inhibition by these compounds did not involve the p38 pathway. It is possible that SB203580 and SB202474 may affect other unknown cellular targets in certain cell types [26] . Cumulatively, our results indicate that the p38 pathway does not participate in TNF-a-induced release of IL-6 by HUCs.
In conclusion, our results demonstrate that TNF-a increases expression and release of IL-6 by HUCs via activation of TNFR1 and that the effects of TNF-a are at least partly mediated by the ERK1/2 and JNK pathways. Interestingly, bladder inflammation created by treatment of rats with cyclophosphamide is associated with phosphorylation of ERK1/2 in bladder urothelial cells [27] and increased IL-6 expression in bladder [28] , and blocking activation of ERK1/2 inhibits bladder hyperreactivity induced by cyclophosphamide [29] , suggesting that ERK1/2 kinase is involved in regulating bladder response to inflammation. Our observation that the ERK1/2 and JNK pathways are involved in the release of pro-inflammatory mediators, such as IL-6 from urothelial cells, together with previous findings, indicate that MAPK ERK1/2 and JNK are potential therapeutic targets for treatment of patients with inflammatory urinary tract diseases. It should be noted that TNF-a-induced IL-6 expression is a complicated process and various signaling pathways are likely to contribute to regulating IL-6 expression, and the observations may vary between different cell lines. Future studies using primarily cultured human urothelial cells will provide a more complete understanding of the regulation of IL-6 expression in urothelial cells.
